What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge
Key takeaways
- URGN COGT SMMT IMVT Superstring Capital Management cut its stake in Uro Gen Pharma Ltd.
- According to a filing with the Securities and Exchange Commission dated May 14, 2026, Superstring Capital Management reduced its position in Uro Gen Pharma Ltd. by 330,983 shares.
- This was a sale, with UroGen Pharma Ltd. representing 4.98% of the fund’s 13F reportable AUM after the move
URGN COGT SMMT IMVT Superstring Capital Management cut its stake in Uro Gen Pharma Ltd. (NASDAQ:URGN), selling 330,983 shares in the first quarter in an estimated $6.64 million trade based on average quarterly pricing, according to a May 14, 2026, SEC filing.
According to a filing with the Securities and Exchange Commission dated May 14, 2026, Superstring Capital Management reduced its position in Uro Gen Pharma Ltd. by 330,983 shares. The estimated transaction value is $6.64 million, based on the average closing price for the quarter ended March 31, 2026. The quarter-end value of the position fell by $9.86 million, reflecting both share sales and price changes.
This was a sale, with UroGen Pharma Ltd. representing 4.98% of the fund’s 13F reportable AUM after the move